# Precision BioSciences Inc. (DTIL) fundamentals

Data as of 2026-11-09. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $9.68, market value $369 million.

## Valuation
- **P/E (trailing): 38.7×** (5-yr avg 3.7×, 3-yr avg 3.7×). Precision BioSciences Inc. trades at 38.7× trailing earnings, well above its own five-year average of 3.7×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×.
- **Price / sales: 8.2×**. Each dollar of revenue is priced at 8.2×.
- **Price / book: 5.2×**. The shares trade at 5.2× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -14.0%** (5-yr avg -120.5%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.
- **Earnings yield: 2.6%**. The inverse of the P/E: 2.6% of the price is earned each year.

## Profitability
- **Operating margin: -80.3%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -133.4%**. The company reported a net loss over the last twelve months.
- **Return on equity: -49.6%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -783.0%**. Return on all capital, debt included, is -783.0%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -25.0%**. Each dollar of assets produces -25.0% of profit.

## Growth
- **Revenue growth (1 yr): -50.1%** (3-yr 10.9%/yr, 5-yr 7.1%/yr). Revenue fell 50.1% over the last year, against 7.1% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -442.3%**. Earnings per share fell 442.3%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.24**. Debt is 0.24 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 2.5×**. It would take 2.5 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 13.32** (quick 13.32). Current assets cover the next year's liabilities 13.32 times.
- **Altman Z-score: 4.70**. A Z-score of 4.70 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Precision BioSciences Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 64.6%** (YTD 154.8%, 3-mo 41.5%). The shares are up 64.6% over twelve months including dividends.
- **From 52-week high: -14.3%** (174.2% above the low). Trading 14% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 81**. An RSI of 81 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 0.68** (volatility 73%). Beta of 0.68 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=DTIL · Page: https://foliofundamentals.com/stocks/dtil

Not investment advice.